It is suggested that epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) should be used for local treatment in patients with EGFR mutation positive brain metastasis of NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.